Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-09-15 00:00:00 ET · period of report 2021-09-13 · accession 0001708138-21-000081 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-15 | 2021-09-13+ | REGN | Zoghbi Huda Y | Dir | S - Sale+OE | $650.00 | -1,000 | 891 | -53% | -$650.0K |
| DM | 2021-09-15 | 2021-09-13+ | REGN | Zoghbi Huda Y | Dir | M - OptEx | $391.92 | +1,000 | 893 | New | +$391.9K |
| DM | 2021-09-15 | 2021-09-13+ | REGN | Zoghbi Huda Y | Dir | M - OptEx | $0.00 | -1,000 | 5,115 | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-14 | S | D | 998 | $650.00 | 891 | D | — | — | |
| 2 | Common | Common Stock | 2021-09-14 | M | A | 998 | $391.92 | 1,889 | D | — | — | |
| 3 | Common | Common Stock | 2021-09-13 | S | D | 2 | $651.10 | 891 | D | — | — | |
| 4 | Common | Common Stock | 2021-09-13 | M | A | 2 | $391.92 | 893 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-09-14 | M | D | 998 | $0.00 | 4,117 | D | $391.92 · — to 2026-09-09 | 998 Common Stock | (F2) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-09-13 | M | D | 2 | $0.00 | 5,115 | D | $391.92 · — to 2026-09-09 | 2 Common Stock | (F2) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |